Font Josep, Ramos-Casals Manuel, de la Red Gloria, Pou Adolf, Casanova Arnau, García-Carrasco Mario, Cervera Ricard, Molina José A, Valls Josep, Bové Albert, Ingelmo Miguel, Graus Francesc
Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
J Rheumatol. 2003 Jul;30(7):1552-7.
To study the clinical course, response to therapy, and longterm outcome of pure sensory neuropathy (PSN) in a series of patients with primary Sjögren's syndrome (SS) followed prospectively in our referral centers.
We studied 15 patients (13 women, 2 men) with primary SS and PSN. All patients fulfilled 4 or more of the European diagnostic criteria.
At diagnosis of PSN, clinical manifestations included numbness and paresthesias (11 patients), trigeminal neuropathy (6 patients), and Adie's pupil syndrome (4 patients). In 7 patients, PSN was diagnosed prior to SS, in 5 the diagnoses were made simultaneously, and in the remaining 3 patients PSN was diagnosed after the appearance of SS symptomatology. The mean duration of the prospective PSN followup was 10 years (range 1-20). The progression of PSN was acute in 1 patient (producing severe dysfunction in less than 1 month), subacute in 3 patients, and in the remaining 11, the symptoms progressed slowly over the ensuing years to other extremities. Patients were treated with corticosteroids (n = 13), cyclophosphamide (n = 4), and intravenous immunoglobulins (n = 1), and 2 patients received no treatment. In spite of treatment, most patients showed an indolent and insidious longterm PSN course.
We found 3 differentiated clinical courses of the PSN in patients with primary SS: subacute progression in less than 1 month (7%), late acceleration of PSN 2-4 years after an initial indolent onset (20%), and a very longterm insidious, chronic evolution (73%). Prospective analysis of the longterm course of PSN shows a chronic and insidious evolution in most patients with PSN and SS, with a poor response to treatment, although stabilization of symptomatology for long periods is often observed.
在我们的转诊中心对一系列原发性干燥综合征(SS)患者进行前瞻性研究,以探讨纯感觉性神经病(PSN)的临床病程、治疗反应及长期预后。
我们研究了15例原发性SS伴PSN的患者(13例女性,2例男性)。所有患者均符合4项或更多欧洲诊断标准。
在PSN诊断时,临床表现包括麻木和感觉异常(11例患者)、三叉神经病变(6例患者)和阿狄瞳孔综合征(4例患者)。7例患者在SS之前被诊断为PSN,5例同时确诊,其余3例在SS症状出现后被诊断为PSN。PSN前瞻性随访的平均时长为10年(范围1 - 20年)。1例患者PSN进展为急性(在不到1个月内出现严重功能障碍),3例为亚急性,其余11例患者的症状在随后几年缓慢进展至其他肢体。患者接受了皮质类固醇治疗(n = 13)、环磷酰胺治疗(n = 4)和静脉注射免疫球蛋白治疗(n = 1),2例患者未接受治疗。尽管进行了治疗,大多数患者的PSN病程仍呈隐匿性且进展缓慢。
我们发现原发性SS患者的PSN有3种不同的临床病程:1个月内亚急性进展(7%)、初始隐匿发作2 - 4年后PSN晚期加速进展(20%)以及非常长期的隐匿性慢性进展(73%)。对PSN长期病程的前瞻性分析显示,大多数PSN和SS患者的病程呈慢性且隐匿性,对治疗反应不佳,尽管症状常可长期稳定。